Today, August 2, 2024, is set aside as the basis for the allocation of shares in Akums Drugs and Pharmaceuticals. Investor engagement in Akums Drugs’ three-day subscription window for its initial public offering was substantial, as evidenced by the fact that it was reserved up to 63.44 times by the deadline for subscriptions. The window closed on Thursday, August 1, 2024. The price range for the Akums Drugs IPO was Rs 646–679 per share, with a lot size of 22 shares. The offering price for the IPO has been set by the business at Rs 679.
Akums Drugs IPO final subscription status
Qualified institutional buyers (QIBs) placed the highest bids (20.80 times higher than non-institutional investors (NIIs), at 42.10 times higher than Akums Drugs IPO. By the closing day of the subscription, Akums Drugs’ retail section had received 20.80 subscriptions.
Akums Drugs IPO allotment status
Today is when the shares of Akums Drugs are supposed to be distributed. Investors can verify the status of the allotment once it has been finalized by going to the BSE’s official website or Link Intime India, the issue registrar. As an alternative, one can go directly to these links and check the allotment status:
Check the BSE’s Akums Drugs IPO Allotment status: https://www.bseindia.com/investors/appli_check.aspx
Several websites that monitor grey market activity indicate that the unlisted shares of Akums Drugs are presently trading at a premium of approximately Rs 140–141, or 20–21 per cent, over the upper band of the IPO price. This suggests that the company’s shares are listed appropriately.
On Tuesday, August 6, 2024, shares of Akums Drugs are expected to be listed on the BSE and NSE. The company’s shares might list between Rs. 820 and Rs. 821 (GMP + Issue Price) based on the current GMP, giving investors a return of more than 20%.
Akums Drugs & Pharmaceuticals, a renowned pharmaceutical contract development and manufacturing company, was founded in 2004 and provides a wide range of pharmaceutical goods and services both domestically and internationally. Among the many dosage forms that Akums create as a CDMO are tablets, capsules, liquid orals, vials, ampoules, blow-filled seals, topical preparations, eye drops, dry powder injections, and gummies.